ライフサイエンスコーパス: sprint

1 Systolic Blood Pressure Intervention Trial (SPRINT).

2 RD-BP) and from October 2010 to August 2015 (SPRINT).

3 d to predict regulators of mis-splicing (RNA-SPRINT).

4 Systolic Blood Pressure Intervention Trial (SPRINT).

5 n a preplanned substudy of participants from SPRINT.

6 This performs well with SPRINT.

7 cted benefit and more predicted risk than in SPRINT.

8 ing speed in a subgroup of participants from SPRINT.

9 c mortality, calibrated to rates reported in SPRINT.

10 .S. adults meet the eligibility criteria for SPRINT.

11 ost of whom would not have been eligible for SPRINT.

12 9): one session of 4 x 30 s cycle ergometer sprints.

13 dles, which were tested in sequential 2-week sprints.

14 idual variabilities during short course 50 m sprints.

15 ons of the preliminary steps of accelerative sprinting.

16 evalent in sports involving repeated maximal sprinting.

17 e the only key aspect governing accelerative sprinting.

18 ging from walking and running to jumping and sprinting.

19 muscle recovery within the first 48 h after sprinting.

20 s (n = 24) at speeds ranging from walking to sprinting.

21 ing rules (detectable HCV RNA at week 24 for SPRINT-2 and at week 12 for RESPOND-2) could be refined

22 In the SPRINT-2 trial, factors that predicted a SVR to triple t

23 rom the Serine Protease Inhibitor Therapy 2 (SPRINT-2) study (treatment-naive patients) and the Retre

24 In SPRINT-2, a week 12 rule with an HCV RNA cutoff of >/= 1

25 rom the Serine Protease Inhibitor Therapy 2 [SPRINT-2] trial) and those who did not respond to prior

26 mm Hg), only a few would have qualified for SPRINT (27.0% and 21.9% of untreated and treated patient

27 portion of whom would have been eligible for SPRINT (5.4% untreated, 13.9% treated) or HOPE-3 (13.9%

28 Of U.S. adults eligible for SPRINT, 51.0% (95% CI: 47.8% to 54.1%) or 8.6 million (9

29 Of the 9361 participants enrolled in SPRINT, 8828 (5578 men [63.2%]; mean [SD] age, 68.0 [9.5

30 Systolic Blood Pressure Intervention Trial (SPRINT), 9361 randomized clinical trial participants 50

31 study was a secondary analysis of data from SPRINT, a randomized clinical trial comparing intensive

32 eds might originate from intrinsically lower sprinting abilities of athletes with BKA or from more co

33 e performance was assessed by using repeated sprint ability (RSA) and Wingate tests.

34 f the primary outcome is to improve repeated sprint ability performance.

35 rength (right + left grip), speed (5 m, 20 m sprints), acceleration (10 to 20 m), agility (figure-of-

36 Systolic Blood Pressure Intervention Trial (SPRINT), adults at high risk for cardiovascular disease

37 t among the 6 key, prespecified subgroups in SPRINT: age >/=75 years, prior cardiovascular disease, c

38 SPRINT allows the biostatistician to concentrate on the

39 p identify subgroups of participants in both SPRINT and ACCORD-BP who had lower versus higher ARRs in

40 eed to occur at 3 times the rate observed in SPRINT and be 3 times more common in the intensive manag

41 s with SBP of 120 mm Hg or higher, including SPRINT and HOPE-3 eligibility, and estimated who may hav

42 ectives: To assess the representativeness of SPRINT and HOPE-3 relative to patients in the United Sta

43 ensor moment arms were maximized to optimize sprint and marathon running performance, and hip muscles

44 of humans worldwide and is linked to reduced sprint and power performance in both elite athletes and

45 alpha-actinin-3 deficiency is detrimental to sprint and power performance in both elite athletes and

46 Picture a predator watching their prey sprint and screech through a field.

47 Despite differences between the SPRINT and target populations, we estimated a similar be

48 correlations were found between 20-m flying sprint and the SST (p < 0.05).

49 t high performance motor activities, such as sprinting and jumping.

50 howing that hip musculature is vital to both sprinting and marathon running.

51 imal distribution of added muscle volume for sprinting and marathon running.

52 For example, sprinting and running are fundamental to many forms of s

53 ffective for enhancing knee joint mechanics, sprint, and agility recovery post-fatigue, while SS is o

54 cultures: Texel DCM-1, Texel LM-30, Biostar Sprint, and SM-181.

55 ing the fatigue response to repeated maximal sprints are unclear.

56 ly agile, scrambling ibex Capra sibirica and sprinting argali Ovis ammon-responded to predation risk

57 Humans sprinting around banked bends change the duration of foo

58 Spectral Parameterization Resolved in Time (SPRiNT) as a novel method for decomposing complex neural

59 care, Eighth Joint National Committee based, SPRINT based) using nationally representative data to an

60 h optimal brain health improved with optimal SPRINT-based BP treatment implementation versus usual ca

61 SPRINT-based BP treatment increased the number of years

62 Optimal implementation of SPRINT-based BP treatment strategy, compared with usual

63 lived free of ASCVD events were greater for SPRINT-based than Eighth Joint National Committee-based

64 ith CKD who met the eligibility criteria for SPRINT between January 1 and December 31, 2019, in the V

65 The current body of sprinting biomechanics literature together with the fron

66 The 2004 Olympic women's 100-metre sprint champion, Yuliya Nesterenko, is assured of fame a

67 Systolic Blood Pressure Intervention Trial (SPRINT), conducted from October 20, 2010, to August 20,

68 Systolic Blood Pressure Intervention Trial (SPRINT), conducted November 2010 through July 2018.

69 and determine the broader population to whom SPRINT could be generalized.

70 ), Maximal Sprinting Speed Test (20-m flying sprint), Countermovement Jump (CMJ), and Standing Long J

71 Overall, 22.2% met the SPRINT criteria, representing 116.2 (95% CI 107.5 to 124

72 nese adults aged 45 years and older who meet SPRINT criteria.

73 Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the benefit of lowering systolic bl

74 ning distance (HSR; 19.81-25.2 km h(-1)) and sprinting distance (SprD; > 25.2 km h(-1)) were analysed

75 , and characteristics of U.S. adults meeting SPRINT eligibility criteria and determine the broader po

76 treated hypertension, the percentage meeting SPRINT eligibility criteria increased with older age, wa

77 SPRINT eligibility criteria were applied to the 1999 to

78 adults who would qualify for treatment under SPRINT eligibility criteria.

79 on) adults with treated hypertension met the SPRINT eligibility criteria.

80 SPRINT eligibility included age >/=50 years, SBP of 130

81 Main limitations include lack of specific SPRINT eligibility information in the CHARLS survey, unc

82 intensive SBP treatment among those meeting SPRINT eligibility.

83 nd quality-adjusted life-years (QALYs) among SPRINT-eligible adults, under 2 alternative treatment st

84 national sources to a hypothetical cohort of SPRINT-eligible adults.

85 six randomised controlled trials (ACCORD BP, SPRINT, ESPRIT, BPROAD, STEP, and CRHCP).

86 Systolic Blood Pressure Intervention Trial (SPRINT) estimated the effect of intensive systolic blood

87 uding total distance covered (TD), number of sprints, fast run distance, accelerations, and decelerat

88 Sprint Fidelis (Fidelis) implantable cardioverter-defibr

89 safety and feasibility of extraction of the Sprint Fidelis (Medtronic, Minneapolis, Minnesota) lead.

90 onsecutive patients undergoing extraction of Sprint Fidelis (models 6930, 6931, 6948, 6949) leads at

91 Sprint Fidelis (SF) (Medtronic, Inc., Minneapolis, Minne

92 urvival analyses on our 3-center database of Sprint Fidelis and Quattro Secure implantable cardiovert

93 cardioverter-defibrillator leads such as the Sprint Fidelis are limited.

94 The reported failure rate of the Sprint Fidelis defibrillator lead has increased to a ran

95 The Sprint Fidelis implantable cardioverter-defibrillator le

96 Extraction of the Sprint Fidelis lead can be performed safely by experienc

97 Recommendations regarding prophylactic Sprint Fidelis lead extraction may warrant reconsiderati

98 Sprint Fidelis leads are prone to pace-sense lead fractu

99 Between May 2005 and August 2009, 349 Sprint Fidelis leads were extracted from 348 patients.

100 A total of 3169 Sprint Fidelis leads were implanted in 11 centers with a

101 The animal's probability of sprinting forward in response to a mechanosensory stimul

102 The Systolic BP Intervention Trial (SPRINT) found that intensive versus standard systolic BP

103 Overall, SPRINT-Gly is 18% and 50% higher in Matthews correlation

104 The method, called SPRINT-Gly, achieved consistent results between ten-fold

105 no differences in the quantity or length of sprints (>24 km h(-1)) between CON and HOT.

106 reat Britain is only weakly heritable across sprint (h(2) = 0.124), middle-distance (h(2) = 0.122) an

107 initial recovery following repeated maximal sprinting in humans.

108 CK-based profiling of in vitrotranscription (SPRINT), in vitro transcribed RNA sequence-specifically

109 The SPRINT inclusion criteria were age >/=50 years, SBP 130

110 Here, we show that repeated maximal sprints induce neuromuscular fatigue accompanied with a

111 quantify the potential benefits and risks of SPRINT intensive goal implementation, we estimated the d

112 xcess serious adverse events incurred if the SPRINT intensive SBP treatment goal were implemented in

113 ntly, in the Systolic BP Intervention Trial (SPRINT), intensive lowering of clinic systolic BP to a t

114 In SPRINT, intensive BP reduction decreased both acute deco

115 nged in a coordinate manner in response to a sprint interval exercise training regimen in humans and

116 Second, we hypothesized that sprint interval training (SIT) also promotes increases i

117 Sprint interval training (SIT) and traditional endurance

118 e exercise performance in adult humans after sprint interval training (SIT) has been attributed to mi

119 Sprint interval training (SIT) has been proposed as a ti

120 Sprint interval training (SIT) has been proposed as a ti

121 Sprint interval training (SIT) has been proposed as a ti

122 We report that a single session of sprint interval training (SIT), but not of moderate inte

123 In human subjects, sprint interval training primarily stimulated synthesis

124 andomized controlled trial and observed that sprint-interval exercise (SIE; n = 14), compared to mode

125 ive phosphorylation (OXPHOS) proteins, while sprint-interval training (SIT) improves respiratory func

126 Systolic Blood Pressure Intervention Trial (SPRINT) is a multicenter randomized clinical trial that

127 The Simple Parallel R INTerface (SPRINT) is a wrapper around such parallelised functions.

128 ximal exercises (i.e. less than 1 min - e.g. sprints, jumps, isometric contractions) exhibits diurnal

129 d, where addition of starter culture Biostar Sprint (Lactobacillus sakei, Staphylococcus carnosus, St

130 resent study provides evidence that repeated sprinting leads to significant decreases in average spee

131 ne in the control group were able to achieve SPRINT levels without antihypertensives.

132 The kinematic changes immediately after sprinting likely protected fatigued hamstrings from exce

133 rdized approach to BP management, as used in SPRINT, may help ensure equitable care and could reduce

134 s with BKA or from more complex adaptions in sprinting mechanics due to the biomechanical and morphol

135 Systolic Blood Pressure Intervention Trial (SPRINT MIND), a multicenter randomized clinical trial th

136 r individuals at risk, most notably from the SPRINT-MIND trial.

137 Systolic Blood Pressure Intervention Trial (SPRINT; N=9361), the Action to Control Cardiovascular Ri

138 RNA was quantified on a NanoString nCounter SPRINT (NanoString Technologies, Seattle, WA).

139 of a heart attack and the leg pain of a 30 s sprint--occurs when muscle gets too little oxygen for it

140 e step from a transition state by a unitary "sprint" of approximately 7.8 nm.

141 t during recovery from an exhaustive 1-2 min sprint on a bicycle ergometer with a workload of 400 W.

142 When executed using SPRINT on an HPC resource of eight processors this compu

143 ed how the Namib Day Gecko, Rhoptropus afer, sprints on ecologically relevant substrates.

144 verage speed between the fastest and slowest sprint (p < 0.001; d = 2.27).

145 Compared with 9361 SPRINT participants (mean [SD] age, 67.9 [9.4] years; 60

146 Among 8,828 SPRINT participants (mean age 67.9 years, 35% women), 60

147 Among SPRINT participants above BP target goal, this cross-sec

148 Of 6,554 SPRINT participants analyzed (mean age 65 years, 37% wom

149 Self-identified non-Hispanic Black SPRINT participants free of diabetes at baseline were in

150 SPRINT participants in the highest predicted benefit sub

151 r rates of dialysis or transplantation among SPRINT participants randomized to intensive treatment, b

152 A total of 7918 SPRINT participants were included in the analysis; 3989

153 Of the 8685 SPRINT participants who were prevalent users of antihype

154 Similarly, among SPRINT participants with baseline LVH (n=605, 7.4%), tho

155 the composite of ADHF events and death among SPRINT participants with baseline malignant LVH.

156 Among SPRINT participants with CKD, worse tubular secretion wa

157 Data from 9,069 SPRINT participants with complete data on covariates wer

158 SPRINT participants with higher baseline predicted CVD r

159 Among SPRINT participants without baseline CVD, the relative r

160 Among SPRINT participants without baseline LVH (n=7559), inten

161 Among 2466 Black SPRINT participants, a higher European ancestry proporti

162 Among 9361 SPRINT patients, 755 patients (8.1%) had a MACE or death

163 ation, body weight loss as well as post-game sprint performance were similar between the two conditio

164 technique modifications affect accelerative sprinting performance and assess whether the hypothetica

165 In this secondary analysis of SPRINT, prevalent users of regimens that contain exclusi

166 e randomized systolic BP intervention on the SPRINT primary cardiovascular composite and all-cause mo

167 tensive (versus standard) BP lowering on the SPRINT primary CVD outcome (a composite of myocardial in

168 and quantified using the NanoString nCounter SPRINT Profiler.

169 mine the acute effects of a maximum repeated sprint protocol on (1) hamstring shear modulus and (2) k

170 ction, before and after a 10 x 30 m repeated sprint protocol.

171 Systolic Blood Pressure Intervention Trial (SPRINT) provide background information and context on th

172 ignificantly positively correlated with 30-m sprinting (r = 0.604, p < 0.05).

173 red horse population that are best suited to sprint racing.

174 Systolic Blood Pressure Intervention Trial (SPRINT) randomized clinical trial compared the efficacy

175 These SPRINT reactions are easily adaptable to portable format

176 We foresee SPRiNT responding to growing neuroscientific interests i

177 ors have questioned the ability to translate SPRINT results into routine clinical practice, in which

178 We generalized the SPRINT results to US adults who would qualify for treatm

179 Systolic Blood Pressure Intervention Trial (SPRINT) results, we propose a systolic blood pressure ta

180 The follow-up protocol for SPRINT routinely assessed two laboratory monitoring AEs

181 monstrate, with naturalistic synthetic data, SPRiNT's capacity to reliably recover time-varying spect

182 on with the release of detailed results from SPRINT's primary analysis.

183 We emphasize SPRiNT's specific strengths compared to other time-frequ

184 lder receiving treatment for hypertension, a SPRINT SBP level of 120 mm Hg or lower was not associate

185 With design sprints, Scrum, Model-View-Controller, and Representatio

186 to explore the correlation between repeated sprint sets (RSS) ability and several physical attribute

187 ic capacity and short repeated accelerations/sprint sets for overall competitive performance in socce

188 Systolic Blood Pressure Intervention Trial (SPRINT) showed significant reductions in death and cardi

189 Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive blood pressure control red

190 Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive control of systolic blood

191 Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive lowering of systolic BP in

192 lgus, fastest take-off time; d = 0.43-1.89), sprint speed (d = 0.57-0.71), and agility (d = 0.80-0.92

193 Fast sprint speed evolved several times in lizards, including

194 the subdigital adhesive toe pad may increase sprint speed in this species.

195 1)) by 26% in HOT compared to CON), but peak sprint speed was 4% higher (P<0.05) in HOT than in CON,

196 ment jump (CMJ) (assessed via OpenCap), 20-m sprint speed, and Illinois agility test performance.

197 veral physical attributes, including maximum sprint speed, maximal aerobic speed, maximal anaerobic s

198 However, peak sprinting speed and execution of successful passes and c

199 bic Shuttle Running Test (V(MASRT)), Maximal Sprinting Speed Test (20-m flying sprint), Countermoveme

200 We found slower maximum sprinting speeds in athletes with BKA, but did not find

201 ss and elastic energy storage at running and sprinting speeds.

202 s ran at self-selected endurance running and sprinting speeds.

203 The MCL-002 (SPRINT) study was a randomised, phase 2 study of patient

204 f diabetes or dementia were screened for the SPRINT substudy from 6 sites in the US.

205 Systolic Blood Pressure Intervention Trial (SPRINT) suggested that a SBP level of lower than 120 mm

206 Coaches should be aware that sprint swimmers produce significant differences in the s

207 Sprinting, swimming, and jumping performance of ectother

208 This study pooled data from SPRINT (Systolic Blood Pressure Intervention Trial) and

209 SPRINT (Systolic Blood Pressure Intervention Trial) demo

210 g one, and 19.5% (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) elig

211 Among 2089 SPRINT (Systolic Blood Pressure Intervention Trial) part

212 Joint National Committee recommendations and SPRINT (Systolic Blood Pressure Intervention Trial) prot

213 re (SBP) treatment goal is in question, with SPRINT (Systolic Blood Pressure Intervention Trial) sugg

214 is for the primary end point considering the SPRINT (Systolic Blood Pressure Intervention Trial) targ

215 We evaluated the participants of SPRINT (Systolic Blood Pressure Intervention Trial) to a

216 SPRINT (Systolic Blood Pressure Intervention Trial) was

217 A total of 8,820 participants in SPRINT (Systolic Blood Pressure Intervention Trial) were

218 This study was a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a r

219 In SPRINT (Systolic Blood Pressure Intervention Trial), a s

220 In the SPRINT (Systolic Blood Pressure Intervention Trial), int

221 In SPRINT (Systolic Blood Pressure Intervention Trial), pat

222 This was a secondary analysis of SPRINT (Systolic Blood Pressure Intervention Trial).

223 baseline and 1 year from stored specimens in SPRINT (Systolic Blood Pressure Intervention Trial).

224 Subgroup analyses of SPRINT (Systolic Blood Pressure Intervention Trial).

225 lure (ADHF) was a frequent common outcome in SPRINT (Systolic Blood Pressure Intervention Trial).

226 , using individual participant data from the SPRINT (Systolic Blood Pressure Intervention Trial; N=93

227 In this secondary analysis of SPRINT (Systolic Pressure Intervention Trial), participa

228 dulus, the only significant change after the sprint task was in the biceps femoris long head (BFlh) w

229 lite players during the games and a repeated sprint test was conducted after the two game trials.

230 , countermovement jumps [CMJ]), the 20-meter sprint test, and the Yo-Yo intermittent recovery test (Y

231 Phe levels are increased following a Wingate sprint test.

232 regulator of dynein-dependent transport) and Sprint (the guanine nucleotide exchange factor for Rab5)

233 Systolic Blood Pressure Intervention Trial (SPRINT), the longer-term incidence of needing dialysis o

234 atistically significant improvements in 40-m sprint time in study I (compared to LR) and in star dril

235 ilance test), and athletic performance (40-m sprint time, long jump distance, and star drill time) in

236 correlations between tlim100 and SST (sum of sprint times), and large negative correlations between Y

237 r study aimed to assess the applicability of SPRINT to Chinese adults.

238 To translate the findings from SPRINT to clinical practice, we developed prediction mod

239 Lastly, we use SPRiNT to demonstrate how aperiodic dynamics relate to m

240 Second, we use SPRiNT to illustrate how aperiodic spectral features flu

241 Systolic Blood Pressure Intervention Trial (SPRINT) to estimate treatment effects and adverse event

242 Athletes increasingly engage in repeated sprint training consisting in repeated short all-out eff

243 en healthy young men performed nine repeated sprint training sessions in either normoxia (F(I)O(2) =

244 We used a microsimulation model to apply SPRINT treatment effects and health care costs from nati

245 Although adoption of the SPRINT treatment strategy would increase the number of C

246 rt disease classification, and data from the SPRINT trial (Systolic Blood Pressure Intervention Trial

247 pertension but no diabetes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial

248 ts that closely resemble participants of the SPRINT trial (Systolic Blood Pressure Trial).

249 METHODS AND Cox models were derived from SPRINT trial data and validated on ACCORD-BP trial data

250 and explore how ambulatory BP data from the SPRINT trial may inform this discussion.

251 The SPRINT trial was conducted between November 1, 2010, and

252 In this secondary analysis of the SPRINT trial, participants with higher baseline projecte

253 sistent with the estimates from the original SPRINT trial.

254 associated with intensive BP lowering in the SPRINT trial.

255 ed on a level surface while contributions to sprinting uphill are more evenly distributed among motio

256 l tournament, using squat, bench press, 30-m sprint, vertical jump, pull-ups and abdominal endurance

257 SPRINT was an open-label, multicentre, randomised contro

258 SPRINT was terminated early due to benefit observed in t

259 In a post hoc analysis of SPRINT, we defined change in eGFR as the percentage chan

260 -level data from 9361 randomized patients in SPRINT, we developed models to predict risk for MACE or

261 covariate, treatment, and outcome data from SPRINT were combined with covariate data from these popu

262 7%] women) who had been randomly assigned in SPRINT were enrolled in the substudy (1448 received inte

263 d the increase in adverse events observed in SPRINT were largely transportable to trial-eligible CKD

264 absolute risks for serious adverse events in SPRINT were used to estimate the number of potential dea

265 Systolic Blood Pressure Intervention Trial (SPRINT), which recruited individuals 50 years or older w

266 Systolic Blood Pressure Intervention Trial (SPRINT), which recruited participants from 102 sites in

267 nsive therapy in mild to moderate CKD, where SPRINT will help to inform practice, as well as where ga

268 ale and eight female swimmers performed 25 m sprints with five isotonic loads (1-2-3-4-5 kg for femal

269 ation of this conceptual scaffold in 'design sprint' workshops for graduate students in the life scie